menu
    • menu

    Company profile for Nasus Pharma

    NEW Drugs in Dev: 3
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Nasus pharma develops powder-based Intranasal ( PBI ) specialized product portfolio, to address acute medical conditions & Public Health Threats. Based on its unique microsphere technology Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations. Intranasal administration is most suitable for those situations in which rapid drug delivery is required ...
    Nasus pharma develops powder-based Intranasal ( PBI ) specialized product portfolio, to address acute medical conditions & Public Health Threats. Based on its unique microsphere technology Nasus Pharma is developing a number of intranasal powder products aimed at assisting patients in several acute emergency situations. Intranasal administration is most suitable for those situations in which rapid drug delivery is required and offers multiple advantages such as rapid drug delivery, ease of use, non-invasiveness, and safety.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Nasus PharmaIsrael Flag
    Country
    Country
    Israel
    Address
    Address
    Yigal Alon 65, Tel Aviv-Jaffa, Israel 6744317
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.nasuspharma.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Nasus Pharma Showcases Intranasal Epinephrine Powder Advantages
    Nasus Pharma Showcases Intranasal Epinephrine Powder Advantages

    17 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/17/3239227/0/en/Nasus-Pharma-to-Present-Data-Highlighting-Superior-Nasal-Deposition-and-Stability-of-Intranasal-Epinephrine-Powder-at-AAAAI-2026.html

    GLOBENEWSWIRE
    17 Feb 2026
    Share Share
    Nasus Pharma Announces Closing Of $15.0 Million Private Placement
    Nasus Pharma Announces Closing Of $15.0 Million Private Placement

    13 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/13/3238057/0/en/Nasus-Pharma-Announces-Closing-of-15-0-Million-Private-Placement.html

    GLOBENEWSWIRE
    13 Feb 2026
    Share Share
    Nasus Pharma Reports Positive Phase 2 Results For NS002 Powder
    Nasus Pharma Reports Positive Phase 2 Results For NS002 Powder

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221623/0/en/Nasus-Pharma-Announces-Positive-Interim-Results-from-Phase-2-Clinical-Study-of-NS002-Intranasal-Epinephrine-Powder.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Nasus Pharma Reports Positive Phase 2 Results For NS002
    Nasus Pharma Reports Positive Phase 2 Results For NS002

    20 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/20/3221623/0/en/Nasus-Pharma-Announces-Positive-Interim-Results-from-Phase-2-Clinical-Study-of-NS002-Intranasal-Epinephrine-Powder.html

    GLOBENEWSWIRE
    20 Jan 2026
    Share Share
    Nasus Pharma Appoints Eyal Rubin As EVP, CFO
    Nasus Pharma Appoints Eyal Rubin As EVP, CFO

    20 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/20/3191893/0/en/Nasus-Pharma-Strengthens-Leadership-Team-Appointing-Eyal-Rubin-as-Executive-Vice-President-and-Chief-Financial-Officer.html

    GLOBENEWSWIRE
    20 Nov 2025
    Share Share
    Nasus Pharma Doses First Patient in Phase 2 NS002 Trial
    Nasus Pharma Doses First Patient in Phase 2 NS002 Trial

    18 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/18/3189920/0/en/Nasus-Pharma-Announces-Initiation-of-Phase-2-Clinical-Study-of-NS002-with-First-Participant-Dosed.html

    GLOBENEWSWIRE
    18 Nov 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search